High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis

Tali Czarnowicki1,2, Hyun Je Kim1, Axel P Villani1

  • 1Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Allergy
|April 5, 2021
PubMed

Insights

Mass cytometry revealed a multicytokine signature in atopic dermatitis (AD) patients, with increased IL-21 and IL-13 expression in T-cells. This finding suggests a potential role for IL-21 in AD pathogenesis and may explain varied responses to targeted therapies.

Area of Science:

  • Immunology
  • Dermatology
  • Systems Biology

Background:

  • Flow cytometry has limitations in analyzing multiple immune cell markers simultaneously.
  • Mass cytometry (CyTOF) enables comprehensive immune profiling by integrating numerous parameters.
  • Previous studies on atopic dermatitis (AD) lacked detailed immune profiling, hindering the development of targeted treatments, and the role of IL-21 in AD was unclear.

Purpose of the Study:

  • To comprehensively profile T-cell polarization in patients with moderate-to-severe atopic dermatitis (AD) using mass cytometry.
  • To investigate the potential role of IL-21 in the pathogenesis of AD.

Main Methods:

  • Utilized mass cytometry (CyTOF) to analyze 24 surface, intracellular markers, and transcription factors in T-cells from 20 AD patients and 15 controls.
  • Employed unsupervised analysis to identify T-cell metaclusters and correlated findings with AD severity.
  • Validated results using immunohistochemistry, immunofluorescence, and qRT-PCR on skin samples.

Main Results:

  • Identified distinct CD4+ and CD8+ T-cell metaclusters, including a novel IL-13+ IL-21+ multicytokine metacluster elevated in AD patients.
  • This IL-21+ metacluster correlated significantly with AD severity.
  • Increased IL-21 expression and its colocalization with IL-13/IL-4R were observed in AD skin lesions.

Conclusions:

  • A multicytokine signature, particularly involving IL-21, characterizes moderate-to-severe AD.
  • The prominent IL-21 signature in both blood and skin suggests a potential pathogenic role for IL-21 in AD.
  • Understanding this signature may help explain variable therapeutic responses to single-cytokine targeted treatments in AD.
Abstract